Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Chloroquine and cinchonine relax rat blood vessels by affecting calcium channels, with chloroquine needing caution in heart patients.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.

Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.

Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.

CTP-543 is generally safe for treating alopecia areata.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Scientists made new substances that can block an enzyme linked to prostate issues and hair loss, with potential for creating a new treatment.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.

5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

5α-reduced progestogens may reduce mood issues and brain damage linked to HIV-1 Tat.

Some oral medications may help treat central serous chorioretinopathy, especially eplerenone, but more research is needed.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Cepharanthine helps reduce cell aging caused by the cancer drug Doxorubicin by boosting cell cleanup processes.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Research on HIV-1 capsid inhibitors has progressed significantly, with the U.S. leading in contributions.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

PCR genotyping in cre-loxP mice can be inaccurate due to unintended gene deletions in non-target tissues.

Rapamycin treatment helps reduce brain inflammation and symptoms of mitochondrial disease by blocking specific pathways in mice.

A new compound effectively inhibits human 5α-reductase 1.